Chordia Therapeutics Inc.
TTSE:190A50.00
JPY
-2.00
(-3.85%)
Chordia Therapeutics Inc.
TSE:190A
(Tokyo Stock Exchange)
Recent
price
50.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.- Similar Companies
- Business
- Chordia Therapeutics Inc. is a clinical-stage biotechnology company specializing in the research and development of innovative, first-in-class small-molecule anti-cancer drugs targeting RNA deregulation stress, a novel therapeutic approach in oncology. The company’s product pipeline includes key drug candidates such as CTX-712, a CLK inhibitor currently in Phase 1/2 clinical trials in the United States for relapsed or refractory malignant cancers; CTX-177, a small-molecule MALT1 inhibitor; CTX-439, a CDK12 inhibitor in the final stages of IND-enabling studies; and a preclinical GCN2 inhibitor program. Chordia operates primarily in Japan and collaborates with external partners for manufacturing, distribution, and sales to advance its therapeutic programs. Founded in 2017 and headquartered in Fujisawa, Japan, Chordia Therapeutics focuses on addressing unmet medical needs in oncology by developing drugs that modulate RNA deregulation stress mechanisms implicated in cancer progression. Recent major developments include receipt of a significant research grant valued at 30 million yen for a project targeting tumors with RNA splicing mutations, to be reflected in the fiscal 2026 financial results. The company has also entered into strategic collaborations, including a foundational agreement with Shionogi Pharma and partnerships with institutions such as Kyoto University and Fujitsu to harness AI and biomarker-driven personalized cancer treatment development. Chordia maintains a disciplined R&D-centric business model, emphasizing exploration, preclinical studies, and clinical trials while outsourcing operational aspects. It has also secured milestone payments through licensing agreements, exemplified by its collaboration with Ono Pharmaceutical for the development of CTX-177. The company continues to expand its pipeline and operational scope through strategic alliances and funding rounds to accelerate its mission of delivering breakthrough cancer therapies globally. The current CEO is Hiroshi Miyake, Ph.D. The company remains listed on the Tokyo Stock Exchange under the ticker 190A.T.